Cholesterol increases from Ocaliva for NASH resolve after discontinuation

Study results showed that while treatment with Ocaliva for nonalcoholic steatohepatitis led to an increase in LDL cholesterol at 12 weeks, levels reverted to baseline 24 weeks after discontinuation.Mohammad S . Siddiqui, MD, from the Virginia Commonwealth University, and colleagues used patient data from the FLINT trial to evaluate the impact of Ocaliva (obeticholic acid or OCA, Pfizer) on atherogenic lipoproteins.“The findings from the FLINT trial have served a major impetus for concomitant use of statin therapy and a priori guidelines with medications targeting the bile acid pathwayRead More

Share on facebook
Share on twitter
Share on linkedin